MX2021013272A - Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80. - Google Patents

Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.

Info

Publication number
MX2021013272A
MX2021013272A MX2021013272A MX2021013272A MX2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A MX 2021013272 A MX2021013272 A MX 2021013272A
Authority
MX
Mexico
Prior art keywords
extracellular domain
fusion proteins
pharmaceutical formulations
formulations containing
present disclosure
Prior art date
Application number
MX2021013272A
Other languages
English (en)
Spanish (es)
Inventor
Yong Quan
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2021013272A publication Critical patent/MX2021013272A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0271Chimeric vertebrates, e.g. comprising exogenous cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021013272A 2019-05-03 2020-05-01 Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80. MX2021013272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842722P 2019-05-03 2019-05-03
PCT/US2020/030946 WO2020227062A1 (en) 2019-05-03 2020-05-01 Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins

Publications (1)

Publication Number Publication Date
MX2021013272A true MX2021013272A (es) 2021-11-17

Family

ID=70847527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013272A MX2021013272A (es) 2019-05-03 2020-05-01 Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.

Country Status (9)

Country Link
US (1) US20220227834A1 (https=)
EP (1) EP3963079A1 (https=)
JP (1) JP7716988B2 (https=)
AR (1) AR118853A1 (https=)
AU (1) AU2020270395A1 (https=)
CA (1) CA3136831A1 (https=)
MX (1) MX2021013272A (https=)
TW (1) TW202108126A (https=)
WO (1) WO2020227062A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
WO2026062544A1 (en) * 2024-09-23 2026-03-26 Pfizer Inc. Sirp alpha fusion protein formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2020227062A1 (en) 2020-11-12
AU2020270395A1 (en) 2021-12-23
EP3963079A1 (en) 2022-03-09
JP2022531387A (ja) 2022-07-06
CA3136831A1 (en) 2020-11-12
AR118853A1 (es) 2021-11-03
JP7716988B2 (ja) 2025-08-01
US20220227834A1 (en) 2022-07-21
TW202108126A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021013272A (es) Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
ZA202109124B (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
ZA202002094B (en) Trispecific proteins and methods of use
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
EA201991207A1 (ru) Новые агонисты tnfr и их применение
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
MX2009004714A (es) Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa.
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
BR112019023856A2 (pt) proteínas triespecíficas que visam msln e métodos de utilização
EA202192888A1 (ru) Соединения и способы нацеливания на тау человека
MX388977B (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso.
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
EP4534107A3 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
WO2019148026A8 (en) Il-22 fc fusion proteins and methods of use
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
WO2019136300A3 (en) Anti-mct1 antibodies and uses thereof
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
WO2020172482A3 (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors
MX2020007628A (es) Composiciones y metodos de uso.
WO2018189661A3 (en) Methods and compounds for treating diabetes